Roche's Genentech unit has figured out why different MEK inhibitors exhibit varying efficacy against BRAF- or KRAS-driven cancers, which could help in the design of next-generation inhibitors with improved therapeutic indexes. Genentech already has one inhibitor for each kind of tumor in clinical trials.